Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

Cardiac surgery for septuagenarians presents unique challenges due to age-related vulnerabilities like slower recovery and ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

Mercy Health — Lourdes Hospital has officially restarted its structural heart program after Dr. Shankho Ganguli performed the ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Hyderabad: Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its first-ever Transcatheter Aortic Valve Replacement (TAVR) procedure.

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with surgery.

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...